Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate ...
22 January 2018 - 11:05PM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, announced today that the
company is applauding a new consensus statement from a team of
international experts with screening recommendations on hereditary
prostate cancer that was published in the Journal of Clinical
Oncology. The consensus recommendations point to the need for
routine obtainment of family history information and hereditary
cancer counselling for men with prostate cancer seen by either a
urologist or oncologist.
“Prostate cancer patients have been an underserved community
with genetic testing and metastatic patients face one the highest
hereditary cancer mutation rates. Despite this fact, we estimate
less than 10 percent of men who meet criteria for hereditary
prostate cancer in the United States are tested today.” said Nicole
Lambert, General Manager, Urology, Myriad Genetics. “As the
global leader in hereditary cancer testing we are dedicated to
driving education and awareness for patients and physicians around
the risks of hereditary prostate cancer. For example, we have
recently taken steps to further enhance myRisk Hereditary Cancer,
our market leading test for hereditary cancer with the recent
addition of the HOXB13 gene which has been linked to hereditary
prostate cancer risk. ”
Recently the National Comprehensive Cancer Network (NCCN)
updated their professional guidelines to support hereditary cancer
testing for all men with metastatic prostate cancer which built
upon previous testing recommendations for men with advanced
prostate cancer and a family history of cancer. “It has become
increasingly apparent that hereditary cancer mutations play a
significant role in assessing individual patient prostate cancer
risk as well as having an increasingly impactful effect in patient
therapeutic selection ,” said Neal D. Shore, M.D., President of the
Large Urology Group Practice Association (LUGPA). “Knowing specific
genetic information may not only affect the life of a prostate
cancer patient but may also potentially affect the lives of his
family members.”
For more information talk with your doctor, visit www.myriad.com
or take the www.hereditarycancerquiz.com.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: stabilizing hereditary cancer
revenue, growing new product volume, expanding reimbursement
coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the consensus recommendations pointing to
the need for routine obtainment of family history information and
hereditary cancer counselling for men with prostate cancer seen by
either a urologist or oncologist; the further enhancement of the
myRisk Hereditary Cancer test with the recent addition of the
HOXB13 gene which has been linked to hereditary prostate cancer
risk; the role hereditary cancer mutations play in prostate cancer
risk and future importance of their role in patient therapy
selection; and the Company’s strategic directives under the caption
“About Myriad Genetics.” These “forward-looking statements”
are based on management’s current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those
described or implied in the forward-looking statements. These risks
include, but are not limited to: the risk that sales and profit
margins of our existing molecular diagnostic tests and
pharmaceutical and clinical services may decline or will not
continue to increase at historical rates; risks related to our
ability to transition from our existing product portfolio to our
new tests; risks related to changes in the governmental or private
insurers’ reimbursement levels for our tests or our ability to
obtain reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services tests and any future tests are terminated or cannot be
maintained on satisfactory terms; risks related to delays or other
problems with operating our laboratory testing facilities; risks
related to public concern over our genetic testing in general or
our tests in particular; risks related to regulatory requirements
or enforcement in the United States and foreign countries and
changes in the structure of the healthcare system or healthcare
payment systems; risks related to our ability to obtain new
corporate collaborations or licenses and acquire new technologies
or businesses on satisfactory terms, if at all; risks related to
our ability to successfully integrate and derive benefits from any
technologies or businesses that we license or acquire, including
but not limited to our acquisition of Assurex, Sividon and the
Clinic; risks related to our projections about the potential market
opportunity for our products; the risk that we or our licensors may
be unable to protect or that third parties will infringe the
proprietary technologies underlying our tests; the risk of
patent-infringement claims or challenges to the validity of our
patents; risks related to changes in intellectual property laws
covering our molecular diagnostic tests and pharmaceutical and
clinical services and patents or enforcement in the United States
and foreign countries, such as the Supreme Court decision in the
lawsuit brought against us by the Association for Molecular
Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading “Risk Factors” contained in
Item 1A of our Annual report on Form 10-K for the fiscal year ended
June 30, 2017, which has been filed with the Securities and
Exchange Commission, as well as any updates to those risk factors
filed from time to time in our Quarterly Reports on Form 10-Q or
Current Reports on Form 8-K.
Media Contact:
Ron
Rogers
(801) 584-3065 rrogers@myriad.com
Investor Contact:Scott Gleason(801)
584-1143sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024